Longitudinal assessment of the dose consistency of botulinum toxin type a (BOTOX®) for cervical dystonia

被引:0
作者
Allison Brashear
Patrick Hogan
Maureen Wooten-Watts
Albert Marchetti
Raf Magar
John Martin
机构
[1] Indiana University Medical Center,Department of Neurology
[2] Puget Sound Movement Disorder and Headache Clinic,undefined
[3] Neurology Specialists of Dallas,undefined
[4] Thomson Health Economics Research,undefined
来源
Advances in Therapy | 2005年 / 22卷
关键词
botulinum toxin type A; cervical dystonia; spasmodic torticollis;
D O I
暂无
中图分类号
学科分类号
摘要
Botulinum toxin type A (BoNT/A) is the principal therapy for patients with cervical dystonia. Repeated treatments over many years are required in most cases. This retrospective review evaluates the dose of BoNT/A used to treat cervical dystonia and the interval between treatments during a 2-year observation period. Outcomes data were abstracted from the medical records of 172 patients at 3 different sites who had received BoNT/A between January and December 1998. A total of 1059 treatments were assessed. Mean per-treatment doses throughout the 2-year study ranged from 241.80 to 254.07 units. The mean interval between treatments was 108.48 days during the first year of observation and 114.14 days during the second year. These findings indicate that doses of and intervals between BoNT/A treatments for cervical dystonia were consistent throughout 2 years of observation.
引用
收藏
页码:49 / 55
页数:6
相关论文
共 66 条
  • [1] Jahanshahi M(1990)Natural history of adult-onset idiopathic torticollis Arch Neurol 47 548-552
  • [2] Marion M.H(1998)Current concepts on the clinical features, aetiology and management of idiopathic cervical dystonia Brain 121 547-560
  • [3] Marsden C.D(1995)Response and immunoresistance to botulinum toxin injections Neurology 45 1743-1746
  • [4] Dauer WT(1986)Double-blind study of botulinum toxin in spasmodic torticollis Lancet 2 245-247
  • [5] Burke RE(1998)Long-term effect of botulinum toxin on impairment and functional health in cervical dystonia Neurology 50 1461-1463
  • [6] Greene P(2002)A randomized, double-masked, crossover comparison of the efficacy and safety of botulinum toxin type A produced from the original bulk toxin source and current bulk toxin source for the treatment of cervical dystonia J Neurol 249 57-63
  • [7] Fahn S(2001)Health related quality of life is improved by botulinum neurotoxin type A in long term treated patients with focal dystonia J Neurol Neurosurg Psychiatry 71 193-199
  • [8] Jankovic J(2000)Duration of effect of botulinum toxin type A in adult patients with cervical dystonia: a retrospective chart review Clin Ther 22 1516-1524
  • [9] Schwartz K(1999)Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up Neurology 53 2102-2107
  • [10] Tsui JK(2001)Long-term therapy for spasmodic dysphonia: acoustic and aerodynamic outcomes Arch Otolaryngol Head Neck Surg 127 393-399